Literature DB >> 10477538

Involvement of cardiotrophin-1 in cardiac myocyte-nonmyocyte interactions during hypertrophy of rat cardiac myocytes in vitro.

K Kuwahara1, Y Saito, M Harada, M Ishikawa, E Ogawa, Y Miyamoto, I Hamanaka, S Kamitani, N Kajiyama, N Takahashi, O Nakagawa, I Masuda, K Nakao.   

Abstract

BACKGROUND: The mechanism responsible for cardiac hypertrophy is currently conceptualized as having 2 components, mediated by cardiac myocytes and nonmyocytes, respectively. The interaction between myocytes and nonmyocytes via growth factors and/or cytokines plays an important role in the development of cardiac hypertrophy. We found that cardiac myocytes showed hypertrophic changes when cocultured with cardiac nonmyocytes. Cardiotrophin-1 (CT-1), a new member of the interleukin-6 family of cytokines, was identified by its ability to induce hypertrophic response in cardiac myocytes. In this study, we used the in vitro coculture system to examine how CT-1 is involved in the interaction between cardiac myocytes and nonmyocytes during the hypertrophy process. METHODS AND
RESULTS: RNase protection assay revealed that CT-1 mRNA levels were 3. 5 times higher in cultured cardiac nonmyocytes than in cultured cardiac myocytes. We developed anti-CT-1 antibodies and found that they significantly inhibited the increased atrial and brain natriuretic peptide secretion and protein synthesis characteristic of hypertrophic changes of myocytes in the coculture. In addition, non-myocyte-conditioned medium rapidly elicited tyrosine phosphorylation of STAT3 and induced an increase in natriuretic peptide secretion and protein synthesis in cultured cardiac myocytes; these effects were partially suppressed by anti-CT-1 antibodies. Finally, the hypertrophic effects of CT-1 and endothelin-1, which we had previously implicated in the hypertrophic activity in the coculture, were additive in cardiac myocytes.
CONCLUSIONS: These results show that CT-1 secreted from cardiac nonmyocytes is significantly involved in the hypertrophic changes of cardiac myocytes in the coculture and suggest that CT-1 is an important local regulator in the process of cardiac hypertrophy.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10477538     DOI: 10.1161/01.cir.100.10.1116

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  31 in total

Review 1.  Physiologic, Pathologic, and Therapeutic Paracrine Modulation of Cardiac Excitation-Contraction Coupling.

Authors:  Joshua Mayourian; Delaine K Ceholski; David M Gonzalez; Timothy J Cashman; Susmita Sahoo; Roger J Hajjar; Kevin D Costa
Journal:  Circ Res       Date:  2018-01-05       Impact factor: 17.367

2.  Plasma biomarkers that reflect determinants of matrix composition identify the presence of left ventricular hypertrophy and diastolic heart failure.

Authors:  Michael R Zile; Stacia M Desantis; Catalin F Baicu; Robert E Stroud; Sheila B Thompson; Catherine D McClure; Shannon M Mehurg; Francis G Spinale
Journal:  Circ Heart Fail       Date:  2011-02-24       Impact factor: 8.790

3.  Suppressor of cytokine signaling-3 is a biomechanical stress-inducible gene that suppresses gp130-mediated cardiac myocyte hypertrophy and survival pathways.

Authors:  H Yasukawa; M Hoshijima; Y Gu; T Nakamura; S Pradervand; T Hanada; Y Hanakawa; A Yoshimura; J Ross; K R Chien
Journal:  J Clin Invest       Date:  2001-11       Impact factor: 14.808

Review 4.  The role of interleukin-6 in the failing heart.

Authors:  K C Wollert; H Drexler
Journal:  Heart Fail Rev       Date:  2001-03       Impact factor: 4.214

Review 5.  Circulating biomarkers in the early detection of hypertensive heart disease: usefulness in the developing world.

Authors:  Dike Ojji; Elena Libhaber; Kim Lamont; Friedrich Thienemann; Karen Sliwa
Journal:  Cardiovasc Diagn Ther       Date:  2020-04

6.  Clenbuterol induces cardiac myocyte hypertrophy via paracrine signalling and fibroblast-derived IGF-1.

Authors:  Pankaj K Bhavsar; Nigel J Brand; Leanne E Felkin; Pradeep K Luther; Martin E Cullen; Magdi H Yacoub; Paul J R Barton
Journal:  J Cardiovasc Transl Res       Date:  2010-06-25       Impact factor: 4.132

Review 7.  Myocardial remodeling with aortic stenosis and after aortic valve replacement: mechanisms and future prognostic implications.

Authors:  William M Yarbrough; Rupak Mukherjee; John S Ikonomidis; Michael R Zile; Francis G Spinale
Journal:  J Thorac Cardiovasc Surg       Date:  2011-07-16       Impact factor: 5.209

8.  Effects of ACE inhibition and angiotensin II type 1 receptor blockade on cardiac function and G proteins in rats with chronic heart failure.

Authors:  H Yoshida; M Takahashi; K Tanonaka; T Maki; Y Nasa; S Takeo
Journal:  Br J Pharmacol       Date:  2001-09       Impact factor: 8.739

9.  Plasma atrial natriuretic peptide and brain natriuretic peptide are increased in septic shock: impact of interleukin-6 and sepsis-associated left ventricular dysfunction.

Authors:  Rochus Witthaut; Christian Busch; Peter Fraunberger; Autar Walli; Dietrich Seidel; Günter Pilz; Ralph Stuttmann; Norbert Speichermann; Ljifane Verner; Karl Werdan
Journal:  Intensive Care Med       Date:  2003-08-12       Impact factor: 17.440

10.  Use of serum fibroblast growth factor 23 vs. plasma B-type natriuretic peptide levels in assessing the pathophysiology of patients with heart failure.

Authors:  Miki Imazu; Hiroyuki Takahama; Makoto Amaki; Yasuo Sugano; Takahiro Ohara; Takuya Hasegawa; Hideaki Kanzaki; Toshihisa Anzai; Naoki Mochizuki; Hiroshi Asanuma; Masanori Asakura; Masafumi Kitakaze
Journal:  Hypertens Res       Date:  2016-09-29       Impact factor: 3.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.